Scarica l'app Stockscreener
10.79
0.28%
0.03
Dopo l'orario di chiusura:
10.62
-0.17
-1.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$10.76
Aprire:
$10.75
Volume 24 ore:
3.71M
Relative Volume:
0.58
Capitalizzazione di mercato:
$7.70B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
1.9097
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+1.41%
1M Prestazione:
+7.68%
6M Prestazione:
-3.66%
1 anno Prestazione:
-5.43%
Intervallo 1D:
$10.65
$10.87
Intervallo di 1 settimana:
$10.58
$11.06
Portata 52W:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.79 | 7.59B | 125.68M | 4.81B | -781.21M | 5.65 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Don't Ignore The Insider Selling In Roivant Sciences - simplywall.st
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Roivant Sciences at BofA Securities: Strategic Shifts and Litigation Focus By Investing.com - Investing.com India
Transcript : Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Roivant Sciences at BofA Securities: Strategic Shifts and Litigation Focus - Investing.com Australia
How To Trade (ROIV) - news.stocktradersdaily.com
(ROIV) On The My Stocks Page - news.stocktradersdaily.com
Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - ADVFN
Roivant Sciences: Primed For Growth With A De-Risked Pipeline (NASDAQ:ROIV) - Seeking Alpha
Roivant sciences president Eric Venker sells $1.02 million in stock By Investing.com - Investing.com India
Roivant sciences president Eric Venker sells $1.02 million in stock - Investing.com
Roivant Sciences stock holds $18 target, management shuffle - Investing.com Australia
Roivant Sciences stock holds $18 target, management shuffle By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains overweight on Roivant Sciences stock - Investing.com Australia
Immunovant makes leadership changes - MSN
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Cantor Fitzgerald maintains overweight on Roivant Sciences stock By Investing.com - Investing.com South Africa
Immunovant, Inc. Announces the Expanded Development of Imvt-1402 into Two New Indications, Sjd and Cle - marketscreener.com
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - marketscreener.com
When (ROIV) Moves Investors should Listen - news.stocktradersdaily.com
Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In - Insider Monkey
ROIV Factor-Based Stock Analysis - Nasdaq
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million By Investing.com - Investing.com UK
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Critical Clinical Data Coming: Roivant's Dual Breakthrough Results in MG and CIDP Studies - Stock Titan
(ROIV) Trading Signals - Stock Traders Daily
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ramaswamy Vivek | 10% Owner |
May 06 '25 |
Sale |
11.47 |
273,959 |
3,142,310 |
39,799,611 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):